ADVERTISEMENT

ADVERTISEMENT

Mayo Clinic + Compugen biotech

d6073aba694c508b19f266b76e633af1.jpg
Mayo Clinic + Compugen biotech

Somehow I missed this release last week, but I did see it in the latest issue of Genetic Engineering & Biotechnology News.

Mayo Clinic is working with a Tel Aviv, Israel-based genomics biobusiness called Compugen Ltd. The project is "targeted at discovering and validating novel biomarkers for diagnosing the presence of unstable atherosclerotic plaques in coronary artery disease and cerebrovascular disease."

While I don't know exactly what that means, it sounds like the project could be good beyond its contribution to medicine.

Here's more from the release:

ADVERTISEMENT

Coronary artery disease (CAD) is the leading cause of death in the developed world and resulted in estimated direct and indirect costs of over $430 billion in the United States in 2007. Vulnerable plaque is regarded as the most common cause of complications from CAD and can lead to increased incidence of heart attack and stroke. Currently, there are no diagnostic tests to identify patients with unstable atherosclerotic plaques, and therefore, the availability of biomarkers for this purpose would represent a significant medical breakthrough.

Compugen expects to utilize its unique discovery engine approach to predict and validate biomarkers related to active atherosclerotic disease. Compugen's integrated analysis will incorporate data derived from biological materials provided by Mayo Clinic, as well as Compugen's proprietary expression and clinical data. Compugen will have exclusive commercialization rights for products resulting from this collaboration. Mayo Clinic is entitled to compensation under the agreement.

Hhhhhmmmm...

I'm going to try to get more on this.

What To Read Next